{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:50:28Z","timestamp":1762429828696},"reference-count":28,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2002,12,11]],"date-time":"2002-12-11T00:00:00Z","timestamp":1039564800000},"content-version":"vor","delay-in-days":71,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2002,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background:\u2002<\/jats:bold> The purpose of this study was to investigate the potential of combining cytosine deaminase\/5\u2010fluorocytosine (CD\/5\u2010FC) gene therapy and radiation therapy (either external beam radiation or radioimmunotherapy [RIT]), for the treatment of prostate cancer.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Tumor xenografts of CD\u2010transduced LNCaP cells grown in the testes of severe combined immunodeficiency (SCID) mice were used to evaluate antitumor effect. The mice were injected intraperitoneally with 500\u2003mg\/kg of 5\u2010FC, or with 5, 15 or 30\u2003mg\/kg of 5\u2010fluorouracil (5\u2010FU), for 9 days. The tumors were treated with fractionated radiation at a dose of 1 or 3\u2003Gy\/day for 3 days, or I\u2010131 labelled anti\u2010prostate specific antigen (anti\u2010PSA) monoclonal antibody (mAb) administration at a subtherapeutic dose of 20 or 80\u2003\u00b5Ci. Intratumoral and serum concentrations of 5\u2010FU were measured using high performance liquid chromatography.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Mice treated with CD\/5\u2010FC gene therapy presented a significant tumor growth inhibition comparable to that obtained with 15\u2003mg\/kg, 5\u2010FU systemic administration without marked weight loss. Treatment with CD\/5\u2010FC gene therapy resulted in higher tumor but lower serum concentrations of 5\u2010FU than treatment with systemic 5\u2010FU chemotherapy. An additive antitumor effect was obtained when CD\/5\u2010FC therapy was combined with 1 Gy irradiation, which by itself did not produce a significant antitumor effect. However, the efficacy of CD\/5\u2010FC therapy was not enhanced when combined with RIT, probably due to poor accumulation of the mAb as the tumor\/blood ratio never exceeded 1.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> These findings indicate that CD\/5\u2010FC gene therapy for prostate cancer may function with enhanced antitumor effect when combined with external beam radiation. However, combining CD\/5\u2010FC gene therapy and RIT using an anti\u2010PSA mAb may not be effective because of insufficient accumulation of the mAb at the target tumors.<\/jats:p>","DOI":"10.1046\/j.1442-2042.2002.00513.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T02:05:50Z","timestamp":1047434750000},"page":"567-576","source":"Crossref","is-referenced-by-count":10,"title":["Potential benefits of combining cytosine deaminase\/5\u2010fluorocytosine gene therapy and irradiation for prostate cancer: Experimental study"],"prefix":"10.1111","volume":"9","author":[{"given":"HIROAKI","family":"KATO","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KIYOSHI","family":"KOSHIDA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KUNIHIKO","family":"YOKOYAMA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ATSUSHI","family":"MIZOKAMI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MIKIO","family":"NAMIKI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,12,11]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"4619","article-title":"In vivo antitumor activity of 5\u2010fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase","volume":"53","author":"Huber BE","year":"1993","journal-title":"Cancer Res."},{"key":"e_1_2_6_3_2","first-page":"1503","article-title":"Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5\u2010fluorocytosine and induce protective immunity to wild type tumor","volume":"54","author":"Mullen CA","year":"1994","journal-title":"Cancer Res."},{"key":"e_1_2_6_4_2","first-page":"4808","article-title":"Enzyme\/prodrug gene therapy: comparison of cytosine deaminase\/5\u2010fluorocytosine versus thymidine kinase\/ganciclovir enzyme\/prodrug systems in a human colorectal carcinoma cell line","volume":"55","author":"Trinh QT","year":"1995","journal-title":"Cancer Res."},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1006\/jsre.1997.5051"},{"key":"e_1_2_6_6_2","first-page":"461","article-title":"In vivo gene therapy for \u03b1\u2010fetoprotein\u2010producing hepatocellular carcinoma by adenovirus\u2010mediated transfer of cytosine deaminase gene","volume":"57","author":"Kanai F","year":"1997","journal-title":"Cancer Res."},{"key":"e_1_2_6_7_2","first-page":"2588","article-title":"Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5\u2010fluorocytosine","volume":"58","author":"Lawrence TS","year":"1998","journal-title":"Cancer Res."},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3300611"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-199909010-00096"},{"key":"e_1_2_6_10_2","first-page":"4205","article-title":"Virally directed cytosine deaminase\/5\u2010fluorocytosine gene therapy enhances radiation response in human cancer xenografts","volume":"57","author":"Hanna NN","year":"1997","journal-title":"Cancer Res."},{"key":"e_1_2_6_11_2","first-page":"4325","article-title":"Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo","volume":"57","author":"Pederson LC","year":"1997","journal-title":"Cancer Res."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301196"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.17.1193"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970729)72:3<477::AID-IJC16>3.0.CO;2-9"},{"key":"e_1_2_6_15_2","first-page":"2181","article-title":"Enhanced antitumor activity of combination radioimmunotherapy (131I\u2010labeled monoclonal antibody A33) with chemotherapy (Fluorouracil)","volume":"57","author":"Tschmelitsch J","year":"1997","journal-title":"Cancer Res."},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004320050326"},{"key":"e_1_2_6_17_2","first-page":"149","article-title":"Radioimmunodetection of prostatic cancer with 125I\u2010labelled antibody against prostatic specific antigen","volume":"110","author":"Larson A","year":"1988","journal-title":"Scand. J. Urol. Nephrol. Suppl."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.2990140303"},{"key":"e_1_2_6_19_2","first-page":"33","article-title":"Radioimmunodetection of cancer with the use of indium\u2010111\u2010labeled monoclonal antibodies","volume":"3","author":"Dillman RO","year":"1987","journal-title":"NCI Monogr."},{"key":"e_1_2_6_20_2","first-page":"513","article-title":"Enhanced tumorigenic and metastatic potential of an androgen\u2010sensitive human prostate cancer cell line, LNCaP, by intratesticular inoculation in SCID mice","volume":"11","author":"Koshida K","year":"1997","journal-title":"Int. J. Oncol."},{"key":"e_1_2_6_21_2","first-page":"2719","article-title":"Intratumoral generation of 5\u2010fluorouracil mediated by an antibody\u2010cytosine deaminase conjugate in combination with 5\u2010fluorocytosine","volume":"54","author":"Wallace PW","year":"1994","journal-title":"Cancer Res."},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj0890114"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.2990220203"},{"key":"e_1_2_6_24_2","first-page":"1584","article-title":"A metastatic and androgen\u2010sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice","volume":"57","author":"Sato N","year":"1997","journal-title":"Cancer Res."},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66992-3"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)64906-1"},{"key":"e_1_2_6_27_2","first-page":"65","article-title":"Increased tumor tissue pressure in association with the growth of rat tumors","volume":"77","author":"Hori K","year":"1986","journal-title":"Jpn. J. Cancer Res."},{"key":"e_1_2_6_28_2","first-page":"334","article-title":"Prostate\u2010specific antigen promoter\/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue\u2010specific adenovirus vector","volume":"60","author":"Latham JP","year":"2000","journal-title":"Cancer Res."},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s003450050181"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1442-2042.2002.00513.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1442-2042.2002.00513.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T23:49:28Z","timestamp":1697327368000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1442-2042.2002.00513.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["10.1046\/j.1442-2042.2002.00513.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1442-2042.2002.00513.x","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}